These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29437026)

  • 1. Vasopressin in Heart Failure.
    Iovino M; Iacoviello M; De Pergola G; Licchelli B; Iovino E; Guastamacchia E; Giagulli VA; Triggiani V
    Endocr Metab Immune Disord Drug Targets; 2018; 18(5):458-465. PubMed ID: 29437026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopressin and Vasopressin Antagonists in Heart Failure.
    Vishram-Nielsen JK; Gustafsson F
    Handb Exp Pharmacol; 2017; 243():307-328. PubMed ID: 28432473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II-Vasopressin Interactions in The Regulation of Cardiovascular Functions. Evidence for an Impaired Hormonal Sympathetic Reflex in Hypertension and Congestive Heart Failure.
    Iovino M; Lisco G; Giagulli VA; Vanacore A; Pesce A; Guastamacchia E; De Pergola G; Triggiani V
    Endocr Metab Immune Disord Drug Targets; 2021; 21(10):1830-1844. PubMed ID: 33745438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating hyponatremia in heart failure.
    Goldsmith SR
    Curr Cardiol Rep; 2006 May; 8(3):204-10. PubMed ID: 17552085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials.
    Urbach J; Goldsmith SR
    Ther Adv Cardiovasc Dis; 2021; 15():1753944720977741. PubMed ID: 33435837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopressin antagonists: role in the management of hyponatremia.
    Yeates KE; Morton AR
    Am J Nephrol; 2006; 26(4):348-55. PubMed ID: 16837788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasopressin receptor antagonists in heart failure.
    Hobbs RE; Tang WH
    Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):177-84. PubMed ID: 18232127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
    Onogawa T; Sakamoto Y; Nakamura S; Nakayama S; Fujiki H; Yamamura Y
    Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S67-76. PubMed ID: 22120095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasopressin and vasopressin receptor antagonists in heart failure.
    Oghlakian G; Klapholz M
    Cardiol Rev; 2009; 17(1):10-5. PubMed ID: 19092365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of vasopressin receptor antagonists.
    Ali F; Guglin M; Vaitkevicius P; Ghali JK
    Drugs; 2007; 67(6):847-58. PubMed ID: 17428103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat.
    Burrell LM; Phillips PA; Risvanis J; Chan RK; Aldred KL; Johnston CI
    Am J Physiol; 1998 Jul; 275(1):H176-82. PubMed ID: 9688911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical effects of vasopressin receptor antagonists in heart failure.
    Gheorghiade M
    Cleve Clin J Med; 2006 Jun; 73 Suppl 2():S24-9; discussion S30-3. PubMed ID: 16786910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2007 Nov; 74(10):1466-75. PubMed ID: 17720144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasopressin-receptor antagonists in heart failure.
    Schweiger TA; Zdanowicz MM
    Am J Health Syst Pharm; 2008 May; 65(9):807-17. PubMed ID: 18436727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure.
    Goldsmith SR
    Am J Cardiol; 2005 May; 95(9A):14B-23B. PubMed ID: 15847853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Congestive heart failure in rats is associated with increased collecting duct vasopressin sensitivity and vasopressin type 2 receptor reexternalization.
    Brønd L; Müllertz KM; Torp M; Nielsen J; Graebe M; Hadrup N; Nielsen S; Christensen S; Jonassen TE
    Am J Physiol Renal Physiol; 2013 Dec; 305(11):F1547-54. PubMed ID: 24089411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
    Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
    Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Progress in management for heart failure: diuretics].
    Aoyagi T; Hirata Y
    Nihon Rinsho; 1993 May; 51(5):1281-6. PubMed ID: 8331795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasopressin and vasopressin receptors in brain edema.
    Zeynalov E; Jones SM; Elliott JP
    Vitam Horm; 2020; 113():291-312. PubMed ID: 32138953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasopressin receptor antagonists in patients with chronic heart failure.
    De Vecchis R; Cantatrione C; Mazzei D
    Herz; 2017 Aug; 42(5):492-497. PubMed ID: 27628642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.